Diflucortolone

Diflucortolone

SCHEMBL10052991

C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1C(=O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 8/20 1.00
NR1I2 O75469 3/20 1.00
HTR2B P41595 1/20 1.00
NR3C1 P04150 8/20 0.71
HIF1A Q16665 7/20 0.71
AR P10275 7/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
LMNA P02545 3/20 0.71
ABCB11 O95342 2/20 0.71
CHRM1 P11229 1/20 0.71
CYP3A4 P08684 7/20 0.62
ADORA3 P0DMS8 2/20 0.62
MAPT P10636 2/20 0.62
ALDH1A1 P00352 2/20 0.62
RAB9A P51151 1/20 0.62
MEN1 O00255 1/20 0.57
ALOX15 P16050 1/20 0.57
KMT2A Q03164 1/20 0.57
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diflucortolone SCHEMBL3796 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL11338795 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL5484149 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL3794 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL11856229 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL3795 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL11855200 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL22040571 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL22039899 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A
Diflucortolone SCHEMBL5484155 1.00 PGR (1.00) PGRNR1I2HTR2BNR3C1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170114088-A1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2017-04-27 US disclosed
US-20170114088-A1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2017-04-27 US disclosed
US-RE46190-E1 High-molecular weight conjugate of steroids NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2016-11-01 US disclosed
US-RE46190-E1 High-molecular weight conjugate of steroids NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2016-11-01 US disclosed
EP-2596007-B1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS TARO PHARMA IND (IL) 2016-01-06 EP disclosed
US-8703878-B2 High-molecular weight conjugate of steroids NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2014-04-22 US disclosed
US-8703878-B2 High-molecular weight conjugate of steroids NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2014-04-22 US disclosed
US-20130211069-A1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2013-08-15 US disclosed
US-20130211069-A1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2013-08-15 US disclosed
WO-2012011106-A1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2012-01-26 WO disclosed
US-20100292414-A1 High-Molecular Weight Conjugate Of Steroids NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2010-11-18 US disclosed
US-20100292414-A1 High-Molecular Weight Conjugate Of Steroids NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114088-A1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS CYP17A1, HSD17B7, HSD17B2 PGR 620/4885NR1I2 262/4885HTR2B 1937/4885
US-20100292414-A1 High-Molecular Weight Conjugate Of Steroids CYP17A1, CYP21A2, HSD17B12 PGR 1614/4885NR1I2 708/4885HTR2B 3671/4885
US-20130211069-A1 PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS CYP17A1, HSD17B7, HSD17B2 PGR 620/4885NR1I2 262/4885HTR2B 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.